Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
RESEARCH TOOLSreports
MREO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.53 - $5.02
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.16M
Market Cap
$447.18M
Enterprise Value$559.22M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 26, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding155,145,600
10 Day Avg. Volume938,134
30 Day Avg. Volume1,157,788
Standard Deviation0.33
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)45.50
Price to Cash Flow (P/CF)-41.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit75.31
Enterprise Value/Ebitda-13.23
Forecast
1Y Price Target
$7.50Price Target Upside161.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Mereo Biopharma Group Plc News
PremiumCompany Announcements
Mereo Biopharma Advances with Key Clinical Updates
PremiumCompany Announcements
Mereo BioPharma: Strong Cash Position Amid Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Partnerships And CollaborationsMereo BioPharma has a partnership with Ultragenyx, allowing for commercialization in Europe, while Ultragenyx handles the US and other markets, with a royalty exchange between the companies.
Regulatory MilestonesAlvelestat has received a positive opinion from the EMA's Committee for Orphan Medicinal Products for Orphan Designation, marking an important milestone in their ongoing partnering process.
Bears Say
Clinical Trial ChallengesThe first interim analysis with a more stringent statistical threshold on a less mature dataset was unlikely to be successful.
---
Ownership Overview
1.34% Insiders
0.10% Mutual Funds
48.03% Other Institutional Investors
49.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $2.52 and its highest was $5.02 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $447.18M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Mar 26, 2025 which is in 33 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Nov 12, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.018 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 155,145,600 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.018. Following the earnings report the stock price went down -4.206%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
---
Mereo Biopharma Group Plc Stock Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency, Hypogonadotropic Hypogonadism in obese men, and Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.
---
MREO Stock 12 Month Forecast
Average Price Target
$7.50
▲(161.32% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
Cara Therapeutics
―
Ardelyx
―
Viking Therapeutics
―
AnaptysBio
―
Best Analysts Covering MREO
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+88.17%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +88.17% per trade.
---